Comparative Pharmacology
Head-to-head clinical analysis: HYDRO RESERP versus METATENSIN 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO RESERP versus METATENSIN 2.
HYDRO-RESERP vs METATENSIN #2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride and promoting diuresis. Reserpine is a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine, serotonin) from adrenergic nerve endings and brain, leading to reduced sympathetic outflow and vasodilation.
METATENSIN #2 contains reserpine and methyclothiazide. Reserpine inhibits vesicular monoamine transporter (VMAT), depleting catecholamines from peripheral neurons. Methyclothiazide inhibits sodium-chloride symporter in distal convoluted tubule, reducing fluid volume.
HYDRO-RESERP contains hydrochlorothiazide (HCTZ) and reserpine. HCTZ: 25-100 mg daily orally; reserpine: 0.125-0.25 mg daily orally. Administer once daily unless intolerable hypotension; then split doses. Avoid doses exceeding HCTZ 100 mg/day and reserpine 0.25 mg/day.
1-2 tablets orally every 12 hours; each tablet contains reserpine 0.1 mg, hydralazine 25 mg, hydrochlorothiazide 15 mg.
None Documented
None Documented
50-100 hours (terminal); prolonged in renal impairment, leading to accumulation on repeated dosing.
12 hours (terminal); clinical context: twice-daily dosing maintains stable plasma levels
Renal: 30-40% as unchanged reserpine; biliary/fecal: 60-70% as metabolites.
Renal (80% unchanged, 15% as glucuronide metabolite); biliary/fecal (5%)
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination